Publications in collaboration with researchers from Complejo Hospitalario de Toledo (1)

2019

  1. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

    Breast Journal, Vol. 25, Núm. 2, pp. 219-225